D.E. Shaw & Co’s OptiNose OPTN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-333,333
| Closed | -$3.06M | – | 4614 |
|
|
2025
Q1 | $3.06M | Hold |
333,333
| – | – | ﹤0.01% | 2283 |
|
|
2024
Q4 | $2.23M | Hold |
333,333
| – | – | ﹤0.01% | 2645 |
|
|
2024
Q3 | $3.35M | Hold |
333,333
| – | – | ﹤0.01% | 2289 |
|
|
2024
Q2 | $5.2M | Buy |
+333,333
| New | +$5.58M | ﹤0.01% | 1810 |
|
|
2022
Q3 | – | Sell |
-6,005
| Closed | -$329K | – | 5433 |
|
|
2022
Q2 | $329K | Sell |
6,005
-1,261
| -17% | -$46.4K | ﹤0.01% | 4313 |
|
|
2022
Q1 | $269K | Buy |
7,266
+4,795
| +194% | +$171K | ﹤0.01% | 4712 |
|
|
2021
Q4 | $60K | Buy |
2,471
+1,520
| +160% | +$50.9K | ﹤0.01% | 5169 |
|
|
2021
Q3 | $43K | Sell |
951
-2,385
| -71% | -$100K | ﹤0.01% | 4842 |
|
|
2021
Q2 | $156K | Sell |
3,336
-108
| -3% | -$5.51K | ﹤0.01% | 4493 |
|
|
2021
Q1 | $191K | Buy |
+3,444
| New | +$210K | ﹤0.01% | 3862 |
|
|
2020
Q3 | – | Sell |
-7,129
| Closed | -$795K | – | 4064 |
|
|
2020
Q2 | $795K | Buy |
7,129
+4,138
| +138% | +$295K | ﹤0.01% | 3078 |
|
|
2020
Q1 | $201K | Buy |
2,991
+909
| +44% | +$91.6K | ﹤0.01% | 3644 |
|
|
2019
Q4 | $288K | Buy |
+2,082
| New | +$270K | ﹤0.01% | 3645 |
|
D.E. Shaw & Co's OPTN Position: Q2 2025 in Review
D.E. Shaw & Co sold out of OptiNose (OPTN) in Q2 2025, closing a stake of 333,333 shares — an estimated $3.06M sold.
D.E. Shaw & Co first reported a position in OPTN in Q4 2019 and held it in 13 quarters. The position peaked at $5.2M in Q2 2024. 0 funds tracked by Wall St. Rank hold OPTN as of Q2 2025.
- D.E. Shaw & Co reported no remaining OptiNose position as of Q2 2025 after selling out during the quarter.
- D.E. Shaw & Co sold 333,333 OptiNose shares in Q2 2025, an estimated $3.06M.
- D.E. Shaw & Co first reported a position in OptiNose in Q4 2019 and held it in 13 quarters.
- D.E. Shaw & Co's OptiNose position peaked at $5.2M in Q2 2024.
- 0 funds tracked by Wall St. Rank held OptiNose as of Q2 2025.
Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.